TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37973713

Group type: EXPERIMENTAL
Intervention: HIV-1 subtype A in Ukrainian patients
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: HIV-1 subtype B in Polish patients
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Presence of drug resistance mutations
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Multidrug resistance mutations in Polish patients
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Risk of transmission of multidrug resistant HIV strains
Number of subjects: 117
Study: 37973784

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (mAbs) or antiviral drugs for COVID-19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other drug treatment strategies (control group)
Number of subjects: 0
Study: 37973795

Group type: EXPERIMENTAL
Intervention: Carborie (400 ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plain water (400 ml)
Number of subjects: 80
Study: 37973806

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging-guided lymphadenectomy
Number of subjects: 258

Group type: COMPARATOR
Intervention: Non-ICG group (conventional laparoscopic lymphadenectomy)
Number of subjects: 258
Study: 37973856

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 210

Group type: COMPARATOR
Intervention: Balloon pre-dilatation stenting
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Intracoronary glycoprotein IIb/IIIa inhibitors
Number of subjects: 210
Study: 37973887

Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Prediction models (logistic regression)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Validation cohort (86 patients with cirrhosis)
Number of subjects: 149
Study: 37973901

Group type: EXPERIMENTAL
Intervention: Anlotinib plus TQB2450 (benmelstobart)
Number of subjects: 31
Study: 37973956

Group type: EXPERIMENTAL
Intervention: ctDNA mutations detected
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ctDNA mutations
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PD-L1 expression in small EVs
Number of subjects: 54
Study: 37974056

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri ATCC PTA 4659 at high dose (1 × 10^11 CFU/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri ATCC PTA 4659 at low dose (1 × 10^9 CFU/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri ATCC PTA 4659
Number of subjects: 0
Study: 37974078

Group type: EXPERIMENTAL
Intervention: Graded recession of inferior oblique muscle (8 mm for amplitude 15 PD to 20 PD with mild IOOA, 10 mm for amplitude 20-30 PD with moderate IOOA, maximum recession for amplitude >30 PD with marked IOOA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Graded recession of inferior oblique muscle
Number of subjects: 40
Study: 37974084

Group type: EXPERIMENTAL
Intervention: Bolus of norepinephrine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Continuous infusion of norepinephrine
Number of subjects: 35
Study: 37974112

Group type: EXPERIMENTAL
Intervention: Full intervention group (e-learning platform, networking platform, and digital care documentation)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Partial intervention group (e-learning and networking platforms)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (usual home care)
Number of subjects: 110
Study: 37974126

Group type: EXPERIMENTAL
Intervention: Caring Contact letters sent by CareSource
Number of subjects: 43000

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 43000
Study: 37974158

Group type: EXPERIMENTAL
Intervention: Peer-delivered substance use screening and brief intervention program
Number of subjects: 100
Study: 37974160

Group type: EXPERIMENTAL
Intervention: Ketamine infusions (up to eight infusions, twice-weekly over four weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (active comparator, twice-weekly over four weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine infusions
Number of subjects: 0
Study: 37974184

Group type: EXPERIMENTAL
Intervention: Intravenous idursulfase
Number of subjects: 55
Study: 37974189

Group type: EXPERIMENTAL
Intervention: Activity Planning group (AP; 'traditional' BA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Activity Engagement group (AE; 'experiential' BA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist group (WL)
Number of subjects: 60
Study: 37974223

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation (HFS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Interactive video-case challenge (IVC)
Number of subjects: 69
Study: 37974229

Group type: EXPERIMENTAL
Intervention: Wearable hip orthosis during overground gait training
Number of subjects: 8
Study: 37974234

Group type: EXPERIMENTAL
Intervention: Video-game based swallowing function training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional swallowing function training
Number of subjects: 78
Study: 37974245

Group type: EXPERIMENTAL
Intervention: In-person visits
Number of subjects: 200

Group type: COMPARATOR
Intervention: Telehealth
Number of subjects: 200
Study: 37974265

Group type: EXPERIMENTAL
Intervention: TAPS Electronic Spanish Platform (TAPS-ESP)
Number of subjects: 1000
Study: 37974284

Group type: EXPERIMENTAL
Intervention: EEG-based BCI-assisted MI training
Number of subjects: 0

Group type: COMPARATOR
Intervention: MI training alone (no BCI)
Number of subjects: 0
Study: 37974280

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring plus treatment guideline
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1601
Study: 37974333

Group type: EXPERIMENTAL
Intervention: eW system (adjustable glaucoma drainage device combined with a novel orbital filtering plate)
Number of subjects: 42
Study: 37974502

Group type: EXPERIMENTAL
Intervention: Roy adaptation model-based strengthening program (RAMBSP) for 12 weeks online group sessions
Number of subjects: 105

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 105
Study: 37975059

Group type: EXPERIMENTAL
Intervention: Intravenous branched chain amino acids (IV-BCAA) - 500 mL/day for 3 days + Lactulose; n = 39
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lactulose alone; n = 37
Number of subjects: 70
Study: 37975371

Group type: EXPERIMENTAL
Intervention: Adjuvant Tislelizumab plus chemotherapy (XELOX regimen: Xeloda plus Oxaliplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone (XELOX regimen)
Number of subjects: 0
Study: 37975434

Group type: EXPERIMENTAL
Intervention: OCTA101 (40-60 IU/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OCTA101 (12.5 IU/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OCTA101
Number of subjects: 30
Study: 37975501

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus (PIB) erector spinae plane block (ESPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intercostal nerve block with patient-controlled intravenous analgesia (ICNB-PCIA)
Number of subjects: 80
Study: 37975597

Group type: EXPERIMENTAL
Intervention: Amlodipine plus standard iron chelation therapy
Number of subjects: 253
Study: 37975839

Group type: EXPERIMENTAL
Intervention: Patient education based on individual needs and circumstances
Number of subjects: 0

Group type: COMPARATOR
Intervention: General practitioners' improved skills in COPD management
Number of subjects: 0
Study: 37975923

Group type: EXPERIMENTAL
Intervention: Bright blue-green light (12,000 lx)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dim red light (5 lx)
Number of subjects: 30
Study: 37976067

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: DAPT (Aspirin 100 mg/d + Clopidogrel 75 mg/d)
Number of subjects: 394
Study: 37976073

Group type: EXPERIMENTAL
Intervention: 2 h-double dose of TDF/FTC (two pills)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 7 days-single dose of TDF/FTC (daily pill)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison between 2 h-double dose and 7 days-single dose
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 2 h-double dose of TDF/FTC
Number of subjects: 23
Study: 37976072

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg twice daily (50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 1175
Study: 37976097

Group type: EXPERIMENTAL
Intervention: Wysa for Chronic Pain digital intervention
Number of subjects: 30
Study: 37976257

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training (CCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MBSR and CCT
Number of subjects: 0
Study: 37976375

Group type: EXPERIMENTAL
Intervention: Blood flow restriction resistance exercise (BFR-RE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Resistance exercise without BFR (Control)
Number of subjects: 45
Study: 37976391

Group type: EXPERIMENTAL
Intervention: Terlipressin (median daily dose 4.3 mg/day, mean duration 6.4 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Terlipressin nonresponse
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cirrhotic cardiomyopathy (CCM)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cardiac variables (ratio of early mitral inflow velocity and mitral annular early diastolic tissue doppler velocity > 12.5)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tissue doppler mitral velocity < 7 cm/s
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Reduction in cardiac index > 20.5% at 72 hours
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pretreatment biomarkers (CysC > 2.2 mg/l)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pretreatment biomarkers (N-terminal proBNP > 350 pg/mL)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pulmonary edema
Number of subjects: 140
Study: 37976444

Group type: EXPERIMENTAL
Intervention: Tiragolumab 600 mg plus atezolizumab 1,200 mg and carboplatin/etoposide (CE)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control (placebo plus atezolizumab 1,200 mg and CE)
Number of subjects: 490
Study: 37976516

Group type: EXPERIMENTAL
Intervention: Strata shunt at performance level (PL) 1.0
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strata shunt at performance level (PL) 1.5
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strata shunt at performance level (PL) 2.5
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Change from PL 1.0 to PL 2.5
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strata shunt at performance level (PL) 0.5
Number of subjects: 36
Study: 37976563

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: COPD education (with or without CBT-I)
Number of subjects: 91
Study: 37976633

Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg Q3W intravenously for up to 35 cycles
Number of subjects: 187

Group type: COMPARATOR
Intervention: chemotherapy (treatment of physician's choice per local/country guidelines)
Number of subjects: 187
Study: 37976654

Group type: EXPERIMENTAL
Intervention: Home-based exercise (HOME)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Supervised group exercise (GROUP)
Number of subjects: 38
Study: 37977094

Group type: EXPERIMENTAL
Intervention: Generalized anxiety at baseline
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Worsening of generalized anxiety over time
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Improvement of generalized anxiety over time
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Worsening of cardiac anxiety over time
Number of subjects: 1353
Study: 37977105

Group type: EXPERIMENTAL
Intervention: First-line treatment for HR+/HER2- mBC in women aged <40
Number of subjects: 14897

Group type: COMPARATOR
Intervention: First-line treatment for HR+/HER2- mBC in women aged 40-69
Number of subjects: 14897

Group type: EXPERIMENTAL
Intervention: First-line treatment for TN mBC in women aged <40
Number of subjects: 14897

Group type: COMPARATOR
Intervention: First-line treatment for TN mBC in women aged 40-69
Number of subjects: 14897

Group type: EXPERIMENTAL
Intervention: First-line treatment for HER2+ mBC in women aged <40
Number of subjects: 14897

Group type: COMPARATOR
Intervention: First-line treatment for HER2+ mBC in women aged 40-69
Number of subjects: 14897
Study: 37977159

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 417

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 417
Study: 37977178

Group type: EXPERIMENTAL
Intervention: Self-reported adherence to antiretroviral therapy (ARV)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Sociodemographic, clinical, and psychosocial factors
Number of subjects: 147
Study: 37977207

Group type: EXPERIMENTAL
Intervention: Differentiated service delivery (DSD) eligibility assessment using WHO criteria
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Longitudinal HIV viral load (VL) monitoring
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Assessment of predictors of virologic failure (VF)
Number of subjects: 761
Study: 37977257

Group type: EXPERIMENTAL
Intervention: Choice architecture intervention (banner of daily school meal menu, waterproof tablecloths, posters on healthy eating habits, playful names displays, new containers for fruits, colored footprints) for one month
Number of subjects: 974

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 974
Study: 37977259

Group type: EXPERIMENTAL
Intervention: Anatomical SYNTAX score
Number of subjects: 0
Study: 37977307

Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia (NA)
Number of subjects: 4353

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 4353

Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia with peripheral block (NAP)
Number of subjects: 4353
Study: 37977324

Group type: EXPERIMENTAL
Intervention: reslizumab
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 141
Study: 37977335

Group type: EXPERIMENTAL
Intervention: Cortico-spinal stimulation (real tDCS) for five days/week for two weeks (T1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cortico-spinal stimulation (real tDCS) for five days/week for two weeks (T4)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cortico-spinal stimulation (real tDCS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham stimulation (placebo tDCS)
Number of subjects: 31
Study: 37977486

Group type: EXPERIMENTAL
Intervention: Standard of care (SC) plus gain-framed messaging (GFM)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Feedback on smoking-related biomarkers
Number of subjects: 188

Group type: COMPARATOR
Intervention: No feedback control
Number of subjects: 188
Study: 37977713

Group type: COMPARATOR
Intervention: Lower dose (1.3 × 10^14 vg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Higher dose (1.3 × 10^15 vg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 37977860

Group type: EXPERIMENTAL
Intervention: Digital platform (METHIS) combined with a training programme for clinicians
Number of subjects: 0
Study: 37977865

Group type: EXPERIMENTAL
Intervention: Tight blood pressure control with norepinephrine infusion targeting intraoperative MAP ≥85 mm Hg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine blood pressure management
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tight blood pressure control
Number of subjects: 80
Study: 37977903

Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy (etoposide and carboplatin) for four to six cycles, followed by maintenance therapy with serplulimab for up to 2 years.
Number of subjects: 36
Study: 37977942

Group type: EXPERIMENTAL
Intervention: C difficile vaccine (200 μg total toxoid)
Number of subjects: 1317

Group type: EXPERIMENTAL
Intervention: C difficile vaccine
Number of subjects: 1317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1317
Study: 37978159

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (25 mg/kg loading dose then 10 mg/kg/6 h for 5 days)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (dose level 1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (dose level 2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 29
Study: 37978197

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus high-dose trastuzumab (6 mg/kg weekly)
Number of subjects: 39
Study: 37978266

Group type: EXPERIMENTAL
Intervention: Manual quantification of volumes of 7 lesions and their spatial location
Number of subjects: 29

Group type: COMPARATOR
Intervention: Automatic 4-class segmentation (without transfer learning)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Transfer learning strategies applied to automatic 4-class segmentation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Segmentations based on transfer learning
Number of subjects: 29
Study: 37978284

Group type: EXPERIMENTAL
Intervention: Tovorafenib (420 mg)
Number of subjects: 77
Study: 37978309

Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg plus ezetimibe)
Number of subjects: 3780

Group type: COMPARATOR
Intervention: High-intensity statin (rosuvastatin 20 mg) monotherapy
Number of subjects: 3780

Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy
Number of subjects: 3780
Study: 37978378

Group type: EXPERIMENTAL
Intervention: Cellular bone allograft (CBA) used as primary graft material (≥ 50% by volume) with augmentation up to 50%
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cellular bone allograft (CBA)
Number of subjects: 86
Study: 37978433

Group type: EXPERIMENTAL
Intervention: Implementation strategies including kick-off event, on-site practice facilitation, and interaction with physician expert consultants.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Remote practice facilitation and web-based tools.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Contextual factors influencing quality improvement efforts.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Initiative fatigue among clinicians and practice staff.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: External support for building capacity for quality improvement.
Number of subjects: 102
Study: 37978452

Group type: EXPERIMENTAL
Intervention: hrHPV testing
Number of subjects: 33000

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 33000
Study: 37978474

Group type: EXPERIMENTAL
Intervention: Injecting autologous platelet-rich fibrin (i-PRF)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control side (no i-PRF injection)
Number of subjects: 21
Study: 37978487

Group type: EXPERIMENTAL
Intervention: Bovine xenograft with platelet-rich fibrin (PRF) membrane
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study: 37978488

Group type: EXPERIMENTAL
Intervention: 38% SDF with 5% NaF varnish
Number of subjects: 220

Group type: COMPARATOR
Intervention: 38% SDF alone
Number of subjects: 220
Study: 37978492

Group type: EXPERIMENTAL
Intervention: Subjects with A1ATD (n=19)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: GOLD 1-3 groups
Number of subjects: 463

Group type: COMPARATOR
Intervention: EwAL group (n=61)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: GOLD 3 subjects
Number of subjects: 463
Study: 37978528

Group type: EXPERIMENTAL
Intervention: Strategies to develop stakeholder interrelationships (35% in Preparation phase, 31% in Implementation phase)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Strategies in the use iterative and evaluative approaches cluster (24% in Preparation phase, 18% in Implementation phase)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Strategies in the provide interactive assistance, use financial approaches, and support staff clusters
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Technical assistance, support for clinicians, and financial approaches
Number of subjects: 287
Study: 37978576

Group type: EXPERIMENTAL
Intervention: Community-based intervention (CBI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 30
Study: 37978577

Group type: EXPERIMENTAL
Intervention: eCAU plus the stepped-care program (DWM and PM+)
Number of subjects: 210

Group type: COMPARATOR
Intervention: eCAU
Number of subjects: 210
Study: 37978951

Group type: EXPERIMENTAL
Intervention: Everolimus, 5 mg/m² orally
Number of subjects: 65
Study: 37979048

Group type: EXPERIMENTAL
Intervention: MRS and ABR in group 1 (BIND-M score 1-4)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group 2 (neonatal hyperbilirubinemia only)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (20 healthy neonates)
Number of subjects: 56
Study: 37979133

Group type: EXPERIMENTAL
Intervention: PVAB regimen (prednisone 40 mg/m2 days 1-5, vinblastine 6 mg/m2 day 1, doxorubicin 40 mg/m2 day 1, bendamustine 120 mg/m2 day 1) every 21 days for 6 cycles
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PVAB regimen
Number of subjects: 89
Study: 37979218

Group type: EXPERIMENTAL
Intervention: d-cycloserine augmentation with group exposure therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 152
Study: 37979594

Group type: EXPERIMENTAL
Intervention: High-dose short-course oral primaquine (7 mg/kg over 7 days)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Standard care (single dose oral primaquine of 0.25 mg/kg)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: High-dose short-course oral primaquine
Number of subjects: 495

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 495
Study: 37979595

Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 37979718

Group type: EXPERIMENTAL
Intervention: Pitolisant (up to 20 mg/d)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512